196 related articles for article (PubMed ID: 19152053)
1. Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain.
Leichsenring A; Andriske M; Bäcker I; Stichel CC; Lübbert H
Naunyn Schmiedebergs Arch Pharmacol; 2009 Jun; 379(6):627-36. PubMed ID: 19152053
[TBL] [Abstract][Full Text] [Related]
2. Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury.
Brownjohn PW; Ashton JC
Neuroscience; 2012 Feb; 203():180-93. PubMed ID: 22210507
[TBL] [Abstract][Full Text] [Related]
3. Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.
Hama A; Sagen J
Brain Res; 2011 Sep; 1412():44-54. PubMed ID: 21813113
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid CB
Li AL; Carey LM; Mackie K; Hohmann AG
J Pharmacol Exp Ther; 2017 Aug; 362(2):296-305. PubMed ID: 28592614
[TBL] [Abstract][Full Text] [Related]
5. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain.
Bridges D; Ahmad K; Rice AS
Br J Pharmacol; 2001 Jun; 133(4):586-94. PubMed ID: 11399676
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
de Lago E; Moreno-Martet M; Cabranes A; Ramos JA; Fernández-Ruiz J
Neuropharmacology; 2012 Jun; 62(7):2299-308. PubMed ID: 22342378
[TBL] [Abstract][Full Text] [Related]
7. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain.
Yu XH; Cao CQ; Martino G; Puma C; Morinville A; St-Onge S; Lessard É; Perkins MN; Laird JMA
Pain; 2010 Nov; 151(2):337-344. PubMed ID: 20696525
[TBL] [Abstract][Full Text] [Related]
8. Analgesic effects of cannabinoid receptor agonist WIN55,212-2 in the nucleus cuneiformis in animal models of acute and inflammatory pain in rats.
Ebrahimzadeh M; Haghparast A
Brain Res; 2011 Oct; 1420():19-28. PubMed ID: 21911208
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT
Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101
[TBL] [Abstract][Full Text] [Related]
10. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats.
Pascual D; Goicoechea C; Suardíaz M; Martín MI
Pain; 2005 Nov; 118(1-2):23-34. PubMed ID: 16213089
[TBL] [Abstract][Full Text] [Related]
11. Sustained antinociceptive effect of cannabinoid receptor agonist WIN 55,212-2 over time in rat model of neuropathic spinal cord injury pain.
Hama A; Sagen J
J Rehabil Res Dev; 2009; 46(1):135-43. PubMed ID: 19533526
[TBL] [Abstract][Full Text] [Related]
12. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
Slivicki RA; Xu Z; Mali SS; Hohmann AG
Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
Ahmed MM; Rajpal S; Sweeney C; Gerovac TA; Allcock B; McChesney S; Patel AU; Tilghman JI; Miranpuri GS; Resnick DK
Spine J; 2010 Dec; 10(12):1049-54. PubMed ID: 20920894
[TBL] [Abstract][Full Text] [Related]
14. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
Rahn EJ; Makriyannis A; Hohmann AG
Br J Pharmacol; 2007 Nov; 152(5):765-77. PubMed ID: 17572696
[TBL] [Abstract][Full Text] [Related]
15. [The cannabinoid system and pain: towards new drugs?].
Beltramo M
J Soc Biol; 2009; 203(1):99-106. PubMed ID: 19358815
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery.
Rahn EJ; Deng L; Thakur GA; Vemuri K; Zvonok AM; Lai YY; Makriyannis A; Hohmann AG
Mol Pain; 2014 Apr; 10():27. PubMed ID: 24742127
[TBL] [Abstract][Full Text] [Related]
17. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
18. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway.
Fakhfouri G; Ahmadiani A; Rahimian R; Grolla AA; Moradi F; Haeri A
Neuropharmacology; 2012 Sep; 63(4):653-66. PubMed ID: 22634229
[TBL] [Abstract][Full Text] [Related]
19. Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes.
Vera G; López-Miranda V; Herradón E; Martín MI; Abalo R
Pharmacol Biochem Behav; 2012 Aug; 102(2):335-43. PubMed ID: 22609797
[TBL] [Abstract][Full Text] [Related]
20. Continuous Intrathecal Infusion of Cannabinoid Receptor Agonists Attenuates Nerve Ligation-Induced Pain in Rats.
Shiue SJ; Peng HY; Lin CR; Wang SW; Rau RH; Cheng JK
Reg Anesth Pain Med; 2017; 42(4):499-506. PubMed ID: 28492437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
